Protein-Protein Interactions (eBook, PDF)

• Format: PDF

Produktbeschreibung

Michael D. Wendt
Protein-Protein Interactions as Drug Targets

Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Kurt Deshayes , Jeremy Murray , Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer

John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection

Nicholas A. Meanwell , David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus

Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces

Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor

Produktdetails

• Verlag: Springer Berlin
• Erscheinungstermin: 26. Juni 2012
• Englisch
• ISBN-13: 9783642289651
• Artikelnr.: 37735700

Inhaltsangabe

Protein-Protein Interactions as Drug Targets.- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer.- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection.- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus.- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces.- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor.

---

Protein-Protein Interactions as Drug Targets.- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer.- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection.- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion - a Focus on Respiratory Syncytial Virus.- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces.- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor.